Skip to main content
Premium Trial:

Request an Annual Quote

Ventana to Develop CDx for Merck KGaA

NEW YORK (GenomeWeb) – Ventana Medical Systems today said that it will collaborate with Merck KGaA on a companion diagnostic test for an undisclosed therapeutic target.

According to the firms, Ventana will develop and validate the CDx test for future clinical studies. Further details of the collaboration were not disclosed.

Tucson, Ariz.-based Ventana, which is part of the Roche Group, has several collaborations with biopharmaceutical firms to develop companion diagnostic products. Among its other partners are Bayer, Pfizer, Boehringer Ingelheim, and Takeda's Millennium unit. Last week it announced a deal to develop a companion diagnostic for a MedImmune drug in development for non-small cell lung cancer.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.